Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 7.9 %

BTX stock opened at $1.09 on Friday. The business’s 50-day moving average is $1.48 and its 200 day moving average is $1.81. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The stock has a market cap of $64.12 million, a price-to-earnings ratio of -0.48 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.